ABOUT THE OBVIOUS EFFICIENCY AND REAL PREDICTIONS OF THE APPLICATION OF ANTI-FNO DRAG «FLAMMEGIS» IN CHRONIC INFLAMMATORY DISEASES OF THE INTESTINE

Introduction: Chronic inflammatory bowel disease (HIBD), namely ulcerative colitis (UC) and Crohn's disease (CD) are among the most severe diseases of the digestive system.

Aim: to study the effeciency of infliximab biosimilar "Flammegis" in chronic inflammatory bowel disease.

Materials and methods. Biological therapy (BT) was carried out under the conditions of the gastroenterology department of the University Hospital of Semey State Medical University according to the developed and generally accepted methodology: the Flammegis intravenously infusion (Infliximab, manufacturer SELLTRION, Republic of Korea, Representative Office EKIS Pharmaceutical Plant CJSC since 2013), every 8 weeks with monitoring of the results of therapy at the beginning of treatment and after each session of the GIBT. The mean follow-up was 1 year 4 months.

Research results: In total, we carried out 41 sessions of the BT. The effectiveness of the GIBT was studied in 20 patients with HVSO: 90% with ulcerative colitis and 10% with Crohn's disease. When conducting a BT, after the first sessions, there was a reduction in stool frequency, a decrease in pathological impurities. After 3 sessions, persistent weight gain, increased hemoglobin levels, decreased leukocyte counts, and a significant decrease in ESR have been observed. The dynamics of fecal calprotectin in its final reflection is not presented, since the present study is still ongoing and there are no completed applications of BT yet.

Conclusions: After using Flammegis in HIBD patients after three months and six months, significant clinical effect was observed, confirmed by positive laboratory dynamics of signs of anemia and inflammatory activity of the disease, with a tendency to increase of this dynamics, as the programmatic application of BT continues, leading to ultimately, to induction of remission and improving the quality of life of patients with HIBD.

Zauresh K. Zhumadilova 1, Alida Sh. Kaskabaeva 1,

Nurgul R. Barkibayeva 1, Zhanna E. Muzdubayeva 1,

Gulbarshyn K. Kalimoldina 1, Araylim M. Aitmukhametova2

 

1 Department of faculty therapy, 2 Resident-gastroentelogy of department of faculty therapy,

Semey State Medical University, Semey, Republic of Kazakhstan

1.          Григорьева Г.А., Мешалкина Н.Ю., Репина И.Б. Неспецифический язвенный колит и болезнь Крона: диагностика и лечение осложненных форм // Клинические перспективы гастроэнтерологии, гепатологии. - 2002.- № 5.- С.34-39.

2.          Халиф И.Л., Лоранская И.Д. Воспалительные заболевания кишечника Неспецифический язвенный колит и болезнь Крона): клиника, диагностика и лечение, – М.:Миклош, 2004.- 88с.

3.          Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic Advances in Gastroenterology. 2015; 8(2): 66–82. doi: 10.1177/1756283X14558193 [PMC free article] [PubMed].

4.          Colombel J.F., Sands B.E., Rutgeerts P., et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017; 66: 839–51.

5.          Cohen B.L., Sachar D.B. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.

6.          Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015; 12(9): 537–45. doi: 10.1038/nrgastro.2015.135 . [PubMed].

7.          Dignass A., Eliakim R., Maaser C., et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis // Journal of Crohn's and Colitis (2012): 56-155 S, http://dx.doi.org/10.1016/j.crohns.2012.09.003

8.          Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis // N Engl J Med. 2005;353:2462–76.

 

 

References:

1. Grigor'eva G.A., Meshalkina N.Yu., Repina I.B. Nespetsificheskii yazvennyi kolit i bolezn' Krona: diagnostika i lechenie oslozhnennykh form [non-specific ulcerative colitis and Crohn's disease: diagnosis and treatment of complicated forms]. Klinicheskie perspektivy gastroenterologii, gepatologii [Clinical prospects of gastroenterology, Hepatology]. 2002. № 5. pp.34-39. [in Russian]

2. Khalif I.L., Loranskaya I.D. Vospalitel'nye zabolevaniya kishechnika. Nespetsificheskii yazvennyi kolit i bolezn' Krona: klinika, diagnostika i lechenie [Non-specific ulcerative colitis and Crohn's disease: сlinical, diagnosis and treatment]. M.:Miklosh, 2004. - 88p. [in Russian]

3.      Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic Advances in Gastroenterology. 2015; 8(2): 66–82. doi: 10.1177/1756283X14558193 [PMC free article] [PubMed].

4.      Colombel J.F., Sands B.E., Rutgeerts P., et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017; 66: 839–51.

5.      Cohen B.L., Sachar D.B. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.

6.      Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015; 12(9): 537–45. doi: 10.1038/nrgastro.2015.135 . [PubMed].

7.      Dignass A., Eliakim R., Maaser C., et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis. 2012: 56-155 S, http://dx.doi.org/10.1016/j.crohns.2012.09.003

8.      Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

Number of Views: 1149


Bibliography link

Жумадилова З.К., Каскабаева А.Ш., Баркибаева Н.Р., Муздубаева Ж.Е., Калимолдина Г.К., Айтмухамбетова А.М. Об эффективности и реальных возможностях применения анти-ФНО препарата «Фламмэгис» при хронических воспалительных заболеваниях кишечника // Наука и Здравоохранение. 2018. 6 (Т.20). С. 143-149.

Zhumadilova Z.K., Kaskabaeva A.Sh., Barkibayeva N.R., Muzdubayeva Zh.E., Kalimoldina G.K., Aitmukhambetova A.M. About the obvious efficiency and real predictions of the application of anti-FNO drag «Flammegis» in chronic inflammatory diseases of the intestine. Nauka i Zdravookhranenie [Science & Healthcare]. 2018, (Vol.20) 6, pp. 143-149.

Жумадилова З.К., Каскабаева А.Ш., Баркибаева Н.Р., Муздубаева Ж.Е., Калимолдина Г.К., Айтмухамбетова А.М. Ішектің сүлелі қабынбалы аурулары кезінде «Фламмэгис» анти-ФНО препараттын қолданудағы нақты болжамдар мен нәтижелігі туралы // Ғылым және Денсаулық сақтау. 2018. 6 (Т.20). Б. 143-149.